GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy
GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among 600 registered teams from 58 countries Selected as one of 8 teams to pitch at the XPRIZE Investor Summit in New York The team is now competing for one of the largest prize pools in the history of XPRIZE SEOUL, South Korea, May 13,...
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance
News Summary Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass., May 13,...
Improved Survival and Growth While Cutting Malnutrition for Premature Infants Fed Human Milk-Based Fortifiers at Sydney Hospital
Study Demonstrates Multiple Benefits of Prolacta's Exclusive Human Milk Diet Compared to Traditional Cow Milk-Based Feeding Protocol ADELAIDE, Australia, May 13, 2025 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products, today announced results from an interim analysis of the Personalised Enteral...
Illuccix China Phase 3 Study Completes Enrolment
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient enrolment. The Phase 3...
United Imaging Expands its U.S. Portfolio with the FDA Clearance of the uAngio® AVIVA for Interventional X-Ray
uAngio AVIVA features the industry's first intelligent voice-assist system, helping medical staff use voice commands and stay focused on their procedures. HOUSTON, May 13, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, announces that its first Interventional X-ray system is now FDA cleared. uAngio AVIVA is an intuitively bionic ceiling-mounted system that uses intelligent...
Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting
SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ("Vitalgen"), will be showcased in one oral presentation and two poster sessions at the American Society of Gene and Cell Therapy (ASGCT)...
AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy
SUZHOU, China, May 12, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held from May 13-17, 2025, in New Orleans, LA. ART001 is the only...
Origin Agritech Hosts Core Customer Symposium in Zhengzhou Kicking-off New Season’s Demonstration and Promotion Activities
BEIJING, May 12, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the successful hosting of its Huanghuai Region Core Customer Symposium in Zhengzhou, Henan Province, where the Company showcased nearly 300 new corn varieties and strengthened strategic relationships with core distributors across the region. The Symposium featured comprehensive...
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints...
YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first domestically approved antibody-drug conjugate (ADC) in China, in combination with the PD-1 inhibitor toripalimab versus...
Prof. Mike Chan’s Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types – with Special Focus on the Brain
HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof. Mike Chan's longstanding vision of organ-specific, cell-specific regenerative medicine. This pivotal research , authored by Prof. Mike Chan and published by Genesis Biomedical Research Institute in collaboration with global universities, represents a transformative leap in...
